Navigation Links
MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
Date:7/24/2008

NEW YORK, July 24 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced results of a Phase 2 clinical trial involving 37 patients who completed a 48-week, U.S. multi-center, open-label efficacy and safety study of EcoNail, a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). The composite primary efficacy endpoint of the trial was "complete cure" defined as negative mycology (negative fungal culture and negative KOH) and clear nail (as determined by expert panel review of clinical photographs). EcoNail is the company's patented, topically-applied lacquer which contains the antifungal econazole and MacroChem's enhancer SEPA(R).

A protocol-mandated, external expert panel assessed clinical photographs of 37 onychomycosis patients who completed 48 weeks of EcoNail treatment. The panel observed that 24 patients (65%) showed evidence of clinical improvement, defined in the protocol as an increase in uninvolved (clear) nail area. While none of the 37 patients reached all criteria of the composite primary endpoint, the consensus judgment of the panel was that 15 of 37 patients (41%) demonstrated significant (greater than or equal to 25%) clinical improvement. All patients had fungal culture-proven nail infections at entry, but after 48 weeks of once-daily treatment with EcoNail, 100% of patients had cultures that were negative for dermatophyte growth. Eight of the 37 patients (22%) achieved the secondary endpoint of negative mycology (negative fugal culture plus negative KOH evaluation) at 48 weeks. The panel observed no signs of local irritation related to the once-daily EcoNail treatment. During the trial, no patient required interruption of dosing due to local intolerability. Through 56 weeks of observation, no cutaneous adverse events were attributed by the investigators to EcoNail.

The laboratory of Boni Elewski, MD, Professor of Dermatology at the University of Alabama-Birmingham, perf
'/>"/>

SOURCE MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
4. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
5. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
6. Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Latin America ... conference dedicated to these diseases.      (Logo: ... Manage Hypertension Online and Manage Thyroid ... EXCEMED - combine the world,s top expertise with ...
(Date:7/3/2015)... , July 3, 2015  Obsidian HDS, the ... an online service for the management of data on ... today that PharmaShine now includes the 2014 Open Payments ... Medicare Services on June 30. The data disclosed on ... transactions between industry and providers totaling $6.49 billion and ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:7/3/2015)... ... , ... The Celebrity Dresses is currently running a promotion through July 30th. ... have the opportunity to get 10% discount on orders that are over $100. , ... to use coupon codes or remember redemption codes. , There is a low ...
(Date:7/2/2015)... ... 2015 , ... The American Association of Poison Control Centers ... Stat (S.O.S.) Act of 2015 on June 23, 2015. Together with the Senate ... drug overdose – especially of heroin and opioid medication – by expanding the ...
(Date:7/2/2015)... ... 02, 2015 , ... “ LIFX ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... light bulbs on the market. , According to the U.S. Department of Energy, it’s ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ZAC Foundation, a national leader ... with important lessons on how to stay water safe with the help of a ... authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. Zeke, who ...
(Date:7/2/2015)... ... July 02, 2015 , ... CleanItSupply.com, ... it has reached an agreement to acquire eRubbermaid.com, an Internet retailer of ... Rubbermaid Commercial Products on the web today. , “eRubbermaid.com’s search ...
Breaking Medicine News(10 mins):Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:CleanItSupply.com Acquires eRubbermaid.com 2
... of the first to implement a 3D cardiac ultrasound machine ... operate.// The machine is a computer designed to show all ... echocardiography system. The artificial intelligence of the system can be ... precise preferences to cardiac surgeons even before they decide on ...
... to researchers from Harvard School of Public Health (HSPH), ... risk of having Parkinson’s disease.// ,Parkinson’s disease ... in their middle ages. Some symptoms of the condition ... a posture. The disease affects the brain cells that ...
... University, while presenting a paper at the AAAS Meeting in ... cooking them to into mashed textures may be one of ... formed. Thus congenital bad shaped teeth may be a direct ... are in bad shape, when compared with teeth of the ...
... to latest research rheumatoid arthritis patients have twice the ... heart's ability // to pump blood, compared to those ... showed patients with rheumatoid arthritis are at an increased ... arthritis, and this risk continues throughout the course of ...
... in the air in many inner-city homes could be ... say researchers. ,According to researchers children living in ... found in mouse urine that is circulating in the ... sensitivity to mice, just as it does for laboratory ...
... a pilot study in New York, air pollution due to ... of the fetus in the womb.// The research was done ... Mailman School of Public Health at Columbia University, US. ... to air pollution due to polycyclic aromatic hydrocarbons (PAH) that ...
Cached Medicine News:
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
... bronchofiberscope yet. The BF-3C40's distal end measures ... the previous model. It also offers better ... to the use of extra-fine optical fibers ... size by 70 percent. Images are clearer, ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
Medicine Products: